Membrane topology of gp41 and amyloid precursor protein: Interfering transmembrane interactions as potential targets for HIV and Alzheimer treatment

Biochimica et Biophysica Acta - Biomembranes

Volumn 1788, Issue 10, 2009, Pages 2132-2141

  Abad, Concepción ^a   Martínez Gil, Luis ^a   Tamborero, Silvia ^a   Mingarro, Ismael ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Alzheimer; Amyloid precursor protein; gp41; HIV; Membrane; Transmembrane segment

Indexed keywords

AMINO ACID; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENFUVIRTIDE; GLYCOPROTEIN; GLYCOPROTEIN GP 41; MARAVIROC; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; PEPTIDOMIMETIC AGENT; SIFUVIRTIDE; TARENFLURBIL; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CLINICAL TRIAL; CONSENSUS SEQUENCE; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BILAYER; MEMBRANE BIOLOGY; MEMBRANE STRUCTURE; MOLECULAR RECOGNITION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROCESSING; REVIEW; SEQUENCE ANALYSIS; VIRUS ENTRY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL MEMBRANE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 70349490456     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2009.07.008     Document Type: Review

References (149)

1. Yin H. Exogenous agents that target transmembrane domains of proteins. Angew Chem. Int. Ed. Engl. 47 (2008) 2744-2752
2. Elofsson A., and von Heijne G. Membrane protein structure: prediction versus reality. Annu. Rev. Biochem. 76 (2007) 125-140
3. Mackenzie K.R. Folding and stability of alpha-helical integral membrane proteins. Chem. Rev. 106 (2006) 1931-1977
4. Cymer F., and Schneider D. Lessons from viruses: controlling the function of transmembrane proteins by interfering transmembrane helices. Curr. Med. Chem. 15 (2008) 779-785
5. Moore D.T., Berger B.W., and DeGrado W.F. Protein-protein interactions in the membrane: sequence, structural, and biological motifs. Structure 16 (2008) 991-1001
6. Yin H., Slusky J.S., Berger B.W., Walters R.S., Vilaire G., Litvinov R.I., Lear J.D., Caputo G.A., Bennett J.S., and DeGrado W.F. Computational design of peptides that target transmembrane helices. Science 315 (2007) 1817-1822
7. Zhu P., Liu J., Bess Jr. J., Chertova E., Lifson J.D., Grise H., Ofek G.A., Taylor K.A., and Roux K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441 (2006) 847-852
8. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 (1998) 1884-1888
9. Colman P.M., and Lawrence M.C. The structural biology of type I viral membrane fusion. Nat. Rev. Mol. Cell Biol. 4 (2003) 309-319
10. Peisajovich S.G., and Shai Y. HIV gp41: a viral membrane fusion machine. In: Fischer W.B. (Ed). Viral Membrane Proteins: Structure, Function and Drug Design vol. 1 (2005), Kluwer Academic/Plenum Publishers, New York 35-47
11. Jacobs A., Garg H., Viard M., Raviv Y., Puri A., and Blumenthal R. HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development. Vaccine 26 (2008) 3026-3035
12. Eckert D.M., and Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70 (2001) 777-810
13. Melikyan G.B. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 5 (2008) 111
14. Melikyan G.B., Markosyan R.M., Hemmati H., Delmedico M.K., Lambert D.M., and Cohen F.S. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151 (2000) 413-423
15. Wexler-Cohen Y., and Shai Y. Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J. 21 (2007) 3677-3684
16. Lev N., Fridmann-Sirkis Y., Blank L., Bitler A., Epand R.F., Epand R.M., and Shai Y. Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action. Biochemistry 48 (2009) 3166-3175
17. Zheng Z., Yang R., Bodner M.L., and Weliky D.P. Conformational flexibility and strand arrangements of the membrane-associated HIV fusion peptide trimer probed by solid-state NMR spectroscopy. Biochemistry 45 (2006) 12960-12975
18. Reichert J., Grasnick D., Afonin S., Buerck J., Wadhwani P., and Ulrich A.S. A critical evaluation of the conformational requirements of fusogenic peptides in membranes. Eur. Biophys. J. 36 (2007) 405-413
19. Li Y., and Tamm L.K. Structure and plasticity of the human immunodeficiency virus gp41 fusion domain in lipid micelles and bilayers. Biophys. J. 93 (2007) 876-885
20. Salom D., Perez-Paya E., Pascal J., and Abad C. Environment- and sequence-dependent modulation of the double-stranded to single-stranded conformational transition of gramicidin A in membranes. Biochemistry 37 (1998) 14279-14291
21. Gabrys C.M., and Weliky D.P. Chemical shift assignment and structural plasticity of a HIV fusion peptide derivative in dodecylphosphocholine micelles. Biochim. Biophys. Acta 1768 (2007) 3225-3234
22. Jaroniec C.P., Kaufman J.D., Stahl S.J., Viard M., Blumenthal R., Wingfield P.T., and Bax A. Structure and dynamics of micelle-associated human immunodeficiency virus gp41 fusion domain. Biochemistry 44 (2005) 16167-16180
23. Han X., Bushweller J.H., Cafiso D.S., and Tamm L.K. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza hemagglutinin. Nat. Struct. Biol. 8 (2001) 715-720
24. Gomara M.J., Mora P., Mingarro I., and Nieva J.L. Roles of a conserved proline in the internal fusion peptide of Ebola glycoprotein. FEBS Lett. 569 (2004) 261-266
25. White J.M., Delos S.E., Brecher M., and Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43 (2008) 189-219
26. Nieva J.L., and Agirre A. Are fusion peptides a good model to study viral cell fusion?. Biochim. Biophys. Acta 1614 (2003) 104-115
27. Sackett K., and Shai Y. The HIV fusion peptide adopts intermolecular parallel beta-sheet structure in membranes when stabilized by the adjacent N-terminal heptad repeat: a 13C FTIR study. J. Mol. Biol. 350 (2005) 790-805
28. Qiang W., and Weliky D.P. HIV fusion peptide and its cross-linked oligomers: efficient syntheses, significance of the trimer in fusion activity, correlation of beta strand conformation with membrane cholesterol, and proximity to lipid headgroups. Biochemistry 48 (2009) 289-301
29. Qiang W., Bodner M.L., and Weliky D.P. Solid-state NMR spectroscopy of human immunodeficiency virus fusion peptides associated with host-cell-like membranes: 2D correlation spectra and distance measurements support a fully extended conformation and models for specific antiparallel strand registries. J. Am. Chem. Soc. 130 (2008) 5459-5471
30. Qiang W., Yang J., and Weliky D.P. Solid-state nuclear magnetic resonance measurements of HIV fusion peptide to lipid distances reveal the intimate contact of beta strand peptide with membranes and the proximity of the Ala-14-Gly-16 region with lipid headgroups. Biochemistry 46 (2007) 4997-5008
31. Callebaut I., Tasso A., Brasseur R., Burny A., Portetelle D., and Mornon J.P. Common prevalence of alanine and glycine in mobile reactive centre loops of serpins and viral fusion peptides: do prions possess a fusion peptide?. J. Comput. Aided Mol. Des. 8 (1994) 175-191
32. Saez-Cirion A., Nieva J.L., and Gallaher W.R. The hydrophobic internal region of bovine prion protein shares structural and functional properties with HIV type 1 fusion peptide. AIDS Res. Hum. Retroviruses 19 (2003) 969-978
33. Gordon L.M., Nisthal A., Lee A.B., Eskandari S., Ruchala P., Jung C.L., Waring A.J., and Mobley P.W. Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein. Biochim. Biophys. Acta 1778 (2008) 2127-2137
34. Lorizate M., Huarte N., Saez-Cirion A., and Nieva J.L. Interfacial pre-transmembrane domains in viral proteins promoting membrane fusion and fission. Biochim. Biophys. Acta 1778 (2008) 1624-1639
35. Salzwedel K., West J.T., and Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73 (1999) 2469-2480
36. Epand R.F., Thomas A., Brasseur R., Vishwanathan S.A., Hunter E., and Epand R.M. Juxtamembrane protein segments that contribute to recruitment of cholesterol into domains. Biochemistry 45 (2006) 6105-6114
37. Epand R.M. Proteins and cholesterol-rich domains. Biochim. Biophys. Acta 1778 (2008) 1576-1582
38. Vishwanathan S.A., Thomas A., Brasseur R., Epand R.F., Hunter E., and Epand R.M. Large changes in the CRAC segment of gp41 of HIV do not destroy fusion activity if the segment interacts with cholesterol. Biochemistry 47 (2008) 11869-11876
39. Vishwanathan S.A., Thomas A., Brasseur R., Epand R.F., Hunter E., and Epand R.M. Hydrophobic substitutions in the first residue of the CRAC segment of the gp41 protein of HIV. Biochemistry 47 (2008) 124-130
40. Luo C., Wang K., Liu de Q., Li Y., and Zhao Q.S. The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention. Cell Mol. Immunol. 5 (2008) 1-7
41. A.A. Waheed, E.O. Freed, Lipids and membrane microdomains in HIV-1 replication, Q5 Virus Res. (in press), doi:10.1016/j.virusres.2009.04.007.
42. Tenchov B.G., MacDonald R.C., and Siegel D.P. Cubic phases in phosphatidylcholine-cholesterol mixtures: cholesterol as membrane "fusogen". Biophys. J. 91 (2006) 2508-2516
43. Vishwanathan S.A., and Hunter E. Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J. Virol. 82 (2008) 5118-5126
44. Chen S.S., Yang P., Ke P.Y., Li H.F., Chan W.E., Chang D.K., Chuang C.K., Tsai Y., and Huang S.C. Identification of the LWYIK motif located in the human immunodeficiency virus type 1 transmembrane gp41 protein as a distinct determinant for viral infection. J. Virol. 83 (2009) 870-883
45. Carter G.C., Bernstone L., Sangani D., Bee J.W., Harder T., and James W. HIV entry in macrophages is dependent on intact lipid rafts. Virology 386 (2009) 192-202
46. Lorizate M., de la Arada I., Huarte N., Sanchez-Martinez S., de la Torre B.G., Andreu D., Arrondo J.L., and Nieva J.L. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence. Biochemistry 45 (2006) 14337-14346
47. Lorizate M., Gomara M.J., de la Torre B.G., Andreu D., and Nieva J.L. Membrane-transferring sequences of the HIV-1 Gp41 ectodomain assemble into an immunogenic complex. J. Mol. Biol. 360 (2006) 45-55
48. Noah E., Biron Z., Naider F., Arshava B., and Anglister J. The membrane proximal external region of the HIV-1 envelope glycoprotein gp41 contributes to the stabilization of the six-helix bundle formed with a matching N' peptide. Biochemistry 47 (2008) 6782-6792
49. Bellamy-McIntyre A.K., Lay C.S., Baar S., Maerz A.L., Talbo G.H., Drummer H.E., and Poumbourios P. Functional links between the fusion peptide-proximal polar segment and membrane-proximal region of human immunodeficiency virus gp41 in distinct phases of membrane fusion. J. Biol. Chem. 282 (2007) 23104-23116
50. Miller M.A., Cloyd M.W., Liebmann J., Rinaldo Jr. C.R., Islam K.R., Wang S.Z., Mietzner T.A., and Montelaro R.C. Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein. Virology 196 (1993) 89-100
51. Srinivas S.K., Srinivas R.V., Anantharamaiah G.M., Segrest J.P., and Compans R.W. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J. Biol. Chem. 267 (1992) 7121-7127
52. Kliger Y., and Shai Y. A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers. Biochemistry 36 (1997) 5157-5169
53. Moreno M.R., Perez-Berna A.J., Guillen J., and Villalain J. Biophysical characterization and membrane interaction of the most membranotropic region of the HIV-1 gp41 endodomain. Biochim. Biophys. Acta 1778 (2008) 1298-1307
54. Jiang J., and Aiken C. Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail. J. Virol. 81 (2007) 9999-10008
55. Viard M., Ablan S.D., Zhou M., Veenstra T.D., Freed E.O., Raviv Y., and Blumenthal R. Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. Biochemistry 47 (2008) 1977-1983
56. Sonigo P., Alizon M., Staskus K., Klatzmann D., Cole S., Danos O., Retzel E., Tiollais P., Haase A., and Wain-Hobson S. Nucleotide sequence of the visna lentivirus: relationship to the AIDS virus. Cell 42 (1985) 369-382
57. Lenz O., Dittmar M.T., Wagner A., Ferko B., Vorauer-Uhl K., Stiegler G., and Weissenhorn W. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J. Biol. Chem. 280 (2005) 4095-4101
58. West J.T., Johnston P.B., Dubay S.R., and Hunter E. Mutations within the putative membrane-spanning domain of the simian immunodeficiency virus transmembrane glycoprotein define the minimal requirements for fusion, incorporation, and infectivity. J. Virol. 75 (2001) 9601-9612
59. Shang L., Yue L., and Hunter E. Role of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein in cell-cell fusion and virus infection. J. Virol. 82 (2008) 5417-5428
60. Marsh D. Protein modulation of lipids, and vice-versa, in membranes. Biochim. Biophys. Acta 1778 (2008) 1545-1575
61. Armstrong R.T., Kushnir A.S., and White J.M. The transmembrane domain of influenza hemagglutinin exhibits a stringent length requirement to support the hemifusion to fusion transition. J. Cell Biol. 151 (2000) 425-437
62. Helseth E., Olshevsky U., Gabuzda D., Ardman B., Haseltine W., and Sodroski J. Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion. J. Virol. 64 (1990) 6314-6318
63. Owens R.J., Burke C., and Rose J.K. Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity. J. Virol. 68 (1994) 570-574
64. Salzwedel K., Johnston P.B., Roberts S.J., Dubay J.W., and Hunter E. Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 67 (1993) 5279-5288
65. Miyauchi K., Komano J., Yokomaku Y., Sugiura W., Yamamoto N., and Matsuda Z. Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. J. Virol. 79 (2005) 4720-4729
66. Welman M., Lemay G., and Cohen E.A. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex. Virus Res. 124 (2007) 103-112
67. Miyauchi K., Curran R., Matthews E., Komano J., Hoshino T., Engelman D.M., and Matsuda Z. Mutations of conserved glycine residues within the membrane-spanning domain of human immunodeficiency virus type 1 gp41 can inhibit membrane fusion and incorporation of Env onto virions. Jpn. J. Infect Dis. 59 (2006) 77-84
68. Lemmon M.A., Flanagan J.M., Treutlein H.R., Zhang J., and Engelman D.M. Sequence specificity in the dimerization of transmembrane α-helices. Biochemistry 31 (1992) 12719-12725
69. Mingarro I., Whitley P., Lemmon M.A., and von Heijne G. Ala-insertion scanning mutagenesis of the glycophorin A transmembrane helix. A rapid way to map helix-helix interactions in integral membrane proteins. Protein Sci. 5 (1996) 1339-1341
70. Melnyk R.A., Kim S., Curran A.R., Engelman D.M., Bowie J.U., and Deber C.M. The affinity of GXXXG motifs in transmembrane helix-helix interactions is modulated by long-range communication. J. Biol. Chem. 279 (2004) 16591-16597
71. Schneider D., and Engelman D.M. Motifs of two small residues can assist but are not sufficient to mediate transmembrane helix interactions. J. Mol. Biol. 343 (2004) 799-804
72. Orzaez M., Salgado J., Gimenez-Giner A., Perez-Paya E., and Mingarro I. Influence of proline residues in transmembrane helix packing. J. Mol. Biol. 335 (2004) 631-640
73. Orzaez M., Perez-Paya E., and Mingarro I. Influence of the C-terminus of the glycophorin A transmembrane fragment on the dimerization process. Protein Sci. 9 (2000) 1246-1253
74. Orzaez M., Lukovic D., Abad C., Perez-Paya E., and Mingarro I. Influence of hydrophobic matching on association of model transmembrane fragments containing a minimised glycophorin A dimerisation motif. FEBS Lett. 579 (2005) 1633-1638
75. Ciczora Y., Callens N., Penin F., Pecheur E.I., and Dubuisson J. Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J. Virol. 81 (2007) 2372-2381
76. Hessa T., Kim H., Bihlmaier K., Lundin C., Boekel J., Andersson H., Nilsson I., White S.H., and von Heijne G. Recognition of transmembrane helices by the endoplasmic reticulum translocon. Nature 433 (2005) 377-381
77. Hessa T., Meindl-Beinker N.M., Bernsel A., Kim H., Sato Y., Lerch-Bader M., Nilsson I., White S.H., and von Heijne G. Molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature 450 (2007) 1026-1030
78. Martinez-Gil L., Perez-Gil J., and Mingarro I. The surfactant peptide KL4 sequence is inserted with a transmembrane orientation into the endoplasmic reticulum membrane. Biophys. J. 95 (2008) L36-38
79. Bentz J. Minimal aggregate size and minimal fusion unit for the first fusion pore of influenza hemagglutinin-mediated membrane fusion. Biophys. J. 78 (2000) 227-245
80. Chertova E., Bess Jr. J.W., Crise B.J., Sowder I.R., Schaden T.M., Hilburn J.M., Hoxie J.A., Benveniste R.E., Lifson J.D., Henderson L.E., and Arthur L.O. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76 (2002) 5315-5325
81. Chien M.P., Lin C.H., and Chang D.K. Recruitment of HIV-1 envelope occurs subsequent to lipid mixing: a fluorescence microscopic evidence. Retrovirology 6 (2009) 20
82. De Clercq E. The design of drugs for HIV and HCV. Nat. Rev. Drug Discov. 6 (2007) 1001-1018
83. Melby T., and Westby M. Inhibitors of viral entry. Handb. Exp. Pharmacol. (2009) 177-202
84. Qian K., Morris-Natschke S.L., and Lee K.H. HIV entry inhibitors and their potential in HIV therapy. Med. Res. Rev. 29 (2009) 369-393
85. Debnath A.K. Prospects and strategies for the discovery and development of small-molecule inhibitors of six-helix bundle formation in class 1 viral fusion proteins. Curr. Opin. Investig. Drugs 7 (2006) 118-127
86. Kaushik-Basu N., Basu A., and Harris D. Peptide inhibition of HIV-1: current status and future potential. BioDrugs 22 (2008) 161-175
87. Oishi S., Ito S., Nishikawa H., Watanabe K., Tanaka M., Ohno H., Izumi K., Sakagami Y., Kodama E., Matsuoka M., and Fujii N. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity. J. Med. Chem. 51 (2008) 388-391
88. He Y., Cheng J., Lu H., Li J., Hu J., Qi Z., Liu Z., Jiang S., and Dai Q. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16332-16337
89. He Y., Cheng J., Li J., Qi Z., Lu H., Dong M., Jiang S., and Dai Q. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J. Virol. 82 (2008) 6349-6358
90. He Y., Xiao Y., Song H., Liang Q., Ju D., Chen X., Lu H., Jing W., Jiang S., and Zhang L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283 (2008) 11126-11134
91. Gomara M.J., Lorizate M., Huarte N., Mingarro I., Perez-Paya E., and Nieva J.L. Hexapeptides that interfere with HIV-1 fusion peptide activity in liposomes block GP41-mediated membrane fusion. FEBS Lett 580 (2006) 2561-2566
92. Gralle M., and Ferreira S.T. Structure and functions of the human amyloid precursor protein: the whole is more than the sum of its parts. Prog. Neurobiol. 82 (2007) 11-32
93. Thinakaran G., and Koo E.H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 283 (2008) 29615-29619
94. Ohsawa I., Takamura C., and Kohsaka S. The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture. Biochem. Biophys. Res. Commun. 236 (1997) 59-65
95. Kong G.K., Adams J.J., Harris H.H., Boas J.F., Curtain C.C., Galatis D., Masters C.L., Barnham K.J., McKinstry W.J., Cappai R., and Parker M.W. Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. J. Mol. Biol. 367 (2007) 148-161
96. Kong G.K., Miles L.A., Crespi G.A., Morton C.J., Ng H.L., Barnham K.J., McKinstry W.J., Cappai R., and Parker M.W. Copper binding to the Alzheimer's disease amyloid precursor protein. Eur. Biophys. J. 37 (2008) 269-279
97. Kaden D., Munter L.M., Joshi M., Treiber C., Weise C., Bethge T., Voigt P., Schaefer M., Beyermann M., Reif B., and Multhaup G. Homophilic interactions of the amyloid precursor protein (APP) ectodomain are regulated by the loop region and affect beta-secretase cleavage of APP. J. Biol. Chem. 283 (2008) 7271-7279
98. Gralle M., Oliveira C.L., Guerreiro L.H., McKinstry W.J., Galatis D., Masters C.L., Cappai R., Parker M.W., Ramos C.H., Torriani I., and Ferreira S.T. Solution conformation and heparin-induced dimerization of the full-length extracellular domain of the human amyloid precursor protein. J. Mol. Biol. 357 (2006) 493-508
99. Gralle M., Botelho M.M., de Oliveira C.L., Torriani I., and Ferreira S.T. Solution studies and structural model of the extracellular domain of the human amyloid precursor protein. Biophys. J. 83 (2002) 3513-3524
100. Menendez-Gonzalez M., Perez-Pinera P., Martinez-Rivera M., Calatayud M.T., and Blazquez Menes B. APP processing and the APP-KPI domain involvement in the amyloid cascade. Neurodegener. Dis. 2 (2005) 277-283
101. Jaeger S., and Pietrzik C.U. Functional role of lipoprotein receptors in Alzheimer's disease. Curr. Alzheimer Res. 5 (2008) 15-25
102. Muller T., Meyer H.E., Egensperger R., and Marcus K. The amyloid precursor protein intracellular domain (AICD) as modulator of gene expression, apoptosis, and cytoskeletal dynamics-relevance for Alzheimer's disease. Prog. Neurobiol. 85 (2008) 393-406
103. McLoughlin D.M., and Miller C.C. The FE65 proteins and Alzheimer's disease. J. Neurosci. Res. 86 (2008) 744-754
104. Scheuermann S., Hambsch B., Hesse L., Stumm J., Schmidt C., Beher D., Bayer T.A., Beyreuther K., and Multhaup G. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. J. Biol. Chem. 276 (2001) 33923-33929
105. Munter L.M., Voigt P., Harmeier A., Kaden D., Gottschalk K.E., Weise C., Pipkorn R., Schaefer M., Langosch D., and Multhaup G. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J. 26 (2007) 1702-1712
106. M. Cruts, http://www.molgen.ua.ac.be/ADMutations, (2009).
107. Beel A.J., Mobley C.K., Kim H.J., Tian F., Hadziselimovic A., Jap B., Prestegard J.H., and Sanders C.R. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?. Biochemistry 47 (2008) 9428-9446
108. Senes A., Gerstein M., and Engelman D.M. Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. J. Mol. Biol. 296 (2000) 921-936
109. Sulistijo E.S., and MacKenzie K.R. Sequence dependence of BNIP3 transmembrane domain dimerization implicates side-chain hydrogen bonding and a tandem GxxxG motif in specific helix-helix interactions. J. Mol. Biol. 364 (2006) 974-990
110. Gorman P., Kim S., Guo M., Melnyk R., McLaurin J., Fraser P., Bowie J., and Chakrabartty A. Dimerization of the transmembrane domain of amyloid precursor proteins and familial Alzheimer's disease mutants. BMC Neuroscience 9 (2008) 17
111. MacKenzie K.R., Prestegard J.H., and Engelman D.M. A transmembrane helix dimer: structure and implications. Science 276 (1997) 131-133
112. Kienlen-Campard P., Tasiaux B., Van Hees J., Li M., Huysseune S., Sato T., Fei J.Z., Aimoto S., Courtoy P.J., Smith S.O., Constantinescu S.N., and Octave J.N. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J. Biol. Chem. 283 (2008) 7733-7744
113. Sato T., Tang T.C., Reubins G., Fei J.Z., Fujimoto T., Kienlen-Campard P., Constantinescu S.N., Octave J.N., Aimoto S., and Smith S.O. A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 1421-1426
114. Miyashita N., Straub J.E., Thirumalai D., and Sugita Y. Transmembrane structures of amyloid precursor protein dimer predicted by replica-exchange molecular dynamics simulations. J. Am. Chem. Soc. 131 (2009) 3438-3439
115. Beel A.J., and Sanders C.R. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol. Life Sci. 65 (2008) 1311-1334
116. Steiner H., Fluhrer R., and Haass C. Intramembrane proteolysis by gamma-secretase. J. Biol. Chem. 283 (2008) 29627-29631
117. Stefani M., and Liguri G. Cholesterol in Alzheimer's disease: unresolved questions. Curr. Alzheimer Res. 6 (2009) 15-29
118. Ehehalt R., Keller P., Haass C., Thiele C., and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160 (2003) 113-123
119. Irvine G.B., El-Agnaf O.M., Shankar G.M., and Walsh D.M. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol. Med. 14 (2008) 451-464
120. Tycko R. Molecular structure of amyloid fibrils: insights from solid-state NMR. Q. Rev. Biophys. 39 (2006) 1-55
121. Glabe C.G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283 (2008) 29639-29643
122. Sato T., Kienlen-Campard P., Ahmed M., Liu W., Li H., Elliott J.I., Aimoto S., Constantinescu S.N., Octave J.N., and Smith S.O. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. Biochemistry 45 (2006) 5503-5516
123. Lundin C., Johansson S., Johnson A.E., Naslund J., von Heijne G., and Nilsson I. Stable insertion of Alzheimer Abeta peptide into the ER membrane strongly correlates with its length. FEBS Lett. 581 (2007) 3809-3813
124. Cheng H., Vetrivel K.S., Gong P., Meckler X., Parent A., and Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease-targeting APP processing in lipid rafts. Nat. Clin. Pract. Neurol. 3 (2007) 374-382
125. Reid P.C., Urano Y., Kodama T., and Hamakubo T. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J. Cell Mol. Med. 11 (2007) 383-392
126. Cordy J.M., Hussain I., Dingwall C., Hooper N.M., and Turner A.J. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11735-11740
127. Schneider A., Rajendran L., Honsho M., Gralle M., Donnert G., Wouters F., Hell S.W., and Simons M. Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28 (2008) 2874-2882
128. Fuentealba R.A., Barria M.I., Lee J., Cam J., Araya C., Escudero C.A., Inestrosa N.C., Bronfman F.C., Bu G., and Marzolo M.P. ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. Mol. Neurodegener. 2 (2007) 14
129. Suzuki T., and Nakaya T. Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions. J. Biol. Chem. 283 (2008) 29633-29637
130. Bai Y., Markham K., Chen F., Weerasekera R., Watts J., Horne P., Wakutani Y., Bagshaw R., Mathews P.M., Fraser P.E., Westaway D., St George-Hyslop P., and Schmitt-Ulms G. The in vivo brain interactome of the amyloid precursor protein. Mol. Cell Proteomics 7 (2008) 15-34
131. Pierrot N., and Octave J.N. Processing of amyloid precursor protein and amyloid peptide neurotoxicity. Curr. Alzheimer Res. 192 (2008) 92-99
132. Barten D.M., and Albright C.F. Therapeutic strategies for Alzheimer's disease. Mol. Neurobiol. 37 (2008) 171-186
133. Forette F., and Hauw J.J. [Alzheimer's disease: from brain lesions to new drugs]. Bull. Acad. Natl. Med. 192 (2008) 363-378 discussion 378-380
134. Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics 5 (2008) 433-442
135. van Marum R.J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol. 22 (2008) 265-274
136. Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr. Med. Chem. 15 (2008) 2433-2455
137. Pepeu G., and Giovannini M.G. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res. 6 (2009) 86-96
138. Shimmyo Y., Kihara T., Akaike A., Niidome T., and Sugimoto H. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim. Biophys. Acta 1780 (2008) 819-825
139. Wolfe M.S. Gamma-secretase inhibition and modulation for Alzheimer's disease. Curr. Alzheimer Res. 5 (2008) 158-164
140. Nitsch R.M., and Hock C. Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Neurotherapeutics 5 (2008) 415-420
141. Wisniewski T., and Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet. Neurol. 7 (2008) 805-811
142. Leissring M.A. The AbetaCs of Abeta-cleaving proteases. J. Biol. Chem. 283 (2008) 29645-29649
143. Doig A.J. Peptide inhibitors of beta-amyloid aggregation. Curr. Opin Drug Discov. Devel. 10 (2007) 533-539
144. Bastianetto S., Krantic S., and Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini. Rev. Med. Chem. 8 (2008) 429-435
145. Bush A.I., and Tanzi R.E. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5 (2008) 421-432
146. Wright T.M. Tramiprosate. Drugs Today (Barc) 42 (2006) 291-298
147. Wilcock G.K., Black S.E., Hendrix S.B., Zavitz K.H., Swabb E.A., and Laughlin M.A. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7 (2008) 483-493
148. Aisen P.S., Gauthier S., Vellas B., Briand R., Saumier D., Laurin J., and Garceau D. Alzhemed: a potential treatment for Alzheimer's disease. Curr. Alzheimer Res. 4 (2007) 473-478
149. Vilar M., Charalampopoulos I., Kenchappa R.S., Simi A., Karaca E., Reversi A., Choi S., Bothwell M., Mingarro I., Friedman W.J., Schiavo G., Bastiaens P.I., Verveer P.J., Carter B.D., and Ibanez C.F. Activation of the p75 neurotrophin receptor through conformational rearrangement of disulphide-linked receptor dimers. Neuron 62 (2009) 72-83